A randomised, open-label, pragmatic pilot comparison of oral and intravenous ketamine in treatment-resistant depression.
Pn Suresh Kumar, Vikas Menon, Chittaranjan Andrade
Asian journal of psychiatry September 1, 2024 DOI: 10.1016/j.ajp.2024.104171 via PubMed
Summary
AI-generated from the abstractIn outpatients with treatment-resistant depression, oral ketamine was better tolerated than intravenous (IV) ketamine, with a lower dropout rate (26.7% vs 54.8%). Depression ratings and response and remission rates did not differ between the two groups at day 14 or day 30. Adverse events such as headache (56.7% vs 74.2%) and drowsiness (0.0% vs 22.6%) were less common with oral ketamine. However, conclusions about relative antidepressant efficacy cannot be drawn due to the high dropout rate in the IV group.
Study at a glance
| Characteristics | Randomized controlled trial Open-label Peer reviewed |
|---|---|
| Sample size | 61 |
| Population | Adults with treatment-resistant depression |
| Interventions | Oral ketamine Intravenous ketamine |
| Dose | Oral: 150 mg in 50 mL water; IV: 0.5 mg/kg |
| Duration | 2-week intervention, 30-day follow-up |
| Topics | Depression Ketamine |
| Keywords | Intravenous ketamine Major depression Oral ketamine Randomized controlled trial |
| Citations | 12 |
| Key finding | Oral ketamine was better tolerated than IV ketamine, with no difference in depression ratings between the two routes, but the high dropout rate in the IV group prevents conclusions about relative efficacy. |
Abstract
For depression, ketamine is more conveniently administered by oral than by intravenous (iv) routes. The relative antidepressant efficacy of oral vs iv ketamine is unknown. To assess the acute efficacy and the persistence of improvement with open-label oral versus iv ketamine in outpatients with treatment-resistant depression (TRD). Adults with TRD were randomized to oral (N=30) or IV (N=31) ketamine. Oral ketamine was dosed at 150 mg in 50 mL of water, sipped across 15 min. IV ketamine was dosed at 0.5 mg/kg, infused across 40 min. Ketamine sessions (total, 7) were administered on alternate days for 2 weeks. Ongoing antidepressant drugs were continued unchanged. Patients were assessed at baseline, day 14, and day 30. The primary outcome was the endpoint Hamilton Rating Scale for Depression score on day 14. Secondary outcomes were endpoint scores on the Montgomery-Asberg Depression Rating Scale, Beck Depression Inventory, and Clinical Global Impression-Severity of Illness and Improvement. Overall dropout was lower with oral than with iv ketamine (26.7 % vs 54.8 %; P=0.03). The 2 groups did not differ in depression ratings and in response and remission rates on all instruments on both days 14 and 30. Adverse events such as headache (56.7 % vs 74.2 %) and drowsiness (0.0 % vs 22.6 %) were less common with oral ketamine. In TRD outpatients treated in general hospitals, oral ketamine maybe better accepted and tolerated than iv ketamine. Conclusions about relative efficacy cannot be drawn because of the high dropout rate with iv ketamine.